Better Therapeutics, Inc. BTTX
0.00 USD 0.00 (+0.00%)
Regular-session close
0.0001 Day range 0.0001
0.0001 52-week range 0.0002
- YTD
- 0.00%
- 1 year
- 0.00%
News
businesswire.com Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc. NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
businesswire.com Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore…
businesswire.com Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
businesswire.com Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
accesswire.com Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big…
zacks.com Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
businesswire.com Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
businesswire.com Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
businesswire.com Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
businesswire.com Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic…
businesswire.com Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
businesswire.com Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
businesswire.com Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
businesswire.com Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today…
businesswire.com Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023 SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today…
benzinga.com Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
businesswire.com Better Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual Conference SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
businesswire.com Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
businesswire.com Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases,…
seekingalpha.com Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane…
